Immediate Substitute for NovoLog in Insulin Pump
Any other rapid-acting insulin analog—specifically insulin lispro (Humalog) or insulin glulisine (Apidra)—can be immediately substituted for insulin aspart (NovoLog) in this patient's insulin pump. 1, 2
Recommended Alternatives
The American Diabetes Association explicitly identifies three rapid-acting insulin analogs as interchangeable for continuous subcutaneous insulin infusion (CSII) pump therapy 1, 2:
- Insulin lispro (Humalog) - preferred alternative with confirmed stability in pump systems 2
- Insulin glulisine (Apidra) - equally appropriate with nearly identical pharmacokinetic profile 1, 3, 4
All three rapid-acting analogs (lispro, aspart, glulisine) share nearly identical pharmacokinetic and pharmacodynamic profiles with onset of 0.25-0.5 hours, peak at 1-3 hours, and duration of 3-5 hours 1, 5, 4. This similarity makes them clinically interchangeable in pump therapy 2, 4.
Why These Work in Pumps
Rapid-acting analogs are the standard choice for insulin pumps because 2:
- Quick onset and early peak allow them to mimic physiologic insulin secretion when delivered continuously
- Confirmed stability in pump systems over 24-hour infusion periods
- The pump delivers approximately 50% of total daily insulin as continuous basal infusion and 50% as meal boluses using the same rapid-acting insulin 2
Critical Safety Points
Never use long-acting insulins (glargine, detemir, degludec) in pumps 2. These are designed for once or twice daily injection, not continuous infusion, and the pump itself provides basal coverage through continuous delivery of rapid-acting insulin 2.
This patient must carry backup rapid-acting insulin syringes or pens 2. Pump malfunction can lead to rapid development of ketoacidosis within hours—a life-threatening emergency—because there is no long-acting insulin depot when using CSII 6, 2.
Switching Considerations
While regular human insulin can technically be used in pumps, it is less optimal 2. Controlled trials demonstrate improved postprandial glucose control with rapid-acting analogs compared to regular insulin when delivered by CSII 2, 4.
The American Diabetes Association recommends that switching between insulin types should be done under medical supervision 1. However, in this urgent situation where the patient is out of medication, switching from NovoLog (aspart) to Humalog (lispro) or Apidra (glulisine) requires minimal adjustment given their nearly identical profiles 1, 5, 4.